A recent review identified seven diseases with a clear neuromuscular involvement that have been targeted by NBS programs over the last twenty years: SMA, PD, DMD, myotonic dystrophy type 1 (MD1), Krabbe disease, X-linked adrenoleukodystrophy (X-ALD), and metachromatic leukodystrophy (MLD) [3]. This evidence concerns the gene LY86 and Duchenne muscular dystrophy.